Reports

The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.

PRIORITY PRESS - 13th International Myeloma Workshop

Increasing Response and Reducing Adverse Events: An Exploration of Dosing Schedules and Combination Therapies for Multiple Myeloma

Paris, France / May 3-6, 2011

Paris - Proteasome inhibitor-containing regimens have improved response rates and response duration across all disease stages of multiple myeloma (MM) in transplant-eligible and -ineligible patients. New data presented here at the Myeloma...

PRIORITY PRESS - 52nd Annual Meeting and Exposition of the American Society of Hematology

A First-line Option for Second-generation TKIs in Chronic Myeloid Leukemia

Orlando, Florida / December 4-7, 2010

Orlando - Second-generation tyrosine kinase inhibitors (TKIs) are replacing imatinib as first-line therapy for Philadelphia chromosome-positive chronic myeloid leukemia (CML), according to practice-changing data presented at the ASH...

PRIORITY PRESS - 52nd Annual Meeting and Exposition of the American Society of Hematology

Evaluating Anticancer Effects of Bisphosphonates in Myeloma

Orlando, Florida / December 4-7, 2010

Orlando - Bisphosphonates have demonstrated efficacy for preventing skeletal-related events in multiple myeloma and other cancers. Beyond the beneficial bone effects, evidence had emerged to suggest that nitrogen-containing bisphosphonates...

PRIORITY PRESS - 52nd Annual Meeting and Exposition of the American Society of Hematology

Expanding Iron Chelation Applications: New Data on Organ Protection

Orlando, Florida / December 4-7, 2010

Orlando - The role of iron chelators, long employed in thalassemia, was supported in an expanding list of both malignant and non-malignant hematological diseases in a series of studies presented at ASH. The ability of iron chelators to...

MEDICAL FRONTIERS - 52nd Annual Meeting and Exposition of the American Society of Hematology

Greater Prophylaxis from Venous Thromboembolism for Cancer Patients

Orlando, Florida / December 4-7, 2010

Orlando - The more than twofold increase in rates of venous thromboembolism (VTE) in cancer patients over a recent 5-year period has identified a growing crisis in comprehensive care of patients with malignancy. The causes of the rising...

PRIORITY PRESS - 52nd Annual Meeting and Exposition of the American Society of Hematology

Validating the Subcutaneous Route in Multiple Myeloma Maintenance Therapy

Orlando, Florida / December 4-7, 2010

Orlando - New phase III data demonstrating that subcutaneous (s.c.) administration of a drug commonly administered intravenously (i.v.) is as effective but better tolerated in the treatment of multiple myeloma (MM) has been proposed as a...

PRIORITY PRESS - 52nd Annual Meeting and Exposition of the American Society of Hematology

Defining Disease Burden and Treatment Efficacy in Paroxysmal Nocturnal Hemoglobinuria

Orlando, Florida / December 4-7, 2010

Orlando - Paroxysmal nocturnal hemoglobinuria (PNH) confers a high risk of morbidity and mortality. In half of patients, the severe and persistent hemolysis that characterizes the disease leads to thromboses involving the liver and cerebral...

FRONTLINE - Hematology/Oncology

Evolving Standards of Therapy in Multiple Myeloma

June 2010

Reviewed and edited by: Kevin W

PRIORITY PRESS - 15th Congress of the European Hematology Association

Update on the Treatment of Iron Overload

Barcelona, Spain / June 10-13, 2010

Barcelona - Patients who become transfusion-dependent due to chronic anemia are highly predisposed to iron overload and iron overload in turn is toxic to many organs. Guidelines indicate that patients with high serum ferritin concentrations...

PAGE 5 OF 10   1 2 3 4 5 6 7 8 9 10